Business Model Breakdown
How Puma Biotechnology Inc Makes Money
PBYI
Market Cap
$308M
Annual Revenue
$238M
Profit Margin
20.3%
Employees
172
The Short Version
Puma Biotechnology is a biopharmaceutical company primarily focused on the development and commercialization of its FDA-approved drug, NERLYNX (neratinib), used for the treatment of certain types of breast cancer. The company generates revenue by selling NERLYNX directly to healthcare providers and through royalties from partners. Its business model relies on the ongoing prescription and patient uptake of NERLYNX, as well as the potential future development of new indications for this drug or other pipeline candidates.
Where the Revenue Comes From
NERLYNX net product revenue (~79% of Q4 2025 total revenue)
Royalty revenue (smaller component, Q1 2026 guidance $2-$3M)
Who buys: Oncology patients (through healthcare providers), and potentially pharmaceutical partners for licensing/royalties.
Why It Works (Competitive Advantages)
- ✔FDA-approved drug (NERLYNX) for specific cancer indications
- ✔Strong balance sheet providing financial stability
Economic Moat: Narrow (Intangible Assets/IP (Patent protection for NERLYNX, though potentially maturing))
What Our Analysis Says
DVR Score as of April 6, 2026
Puma Biotechnology presents an extremely speculative investment for 10x growth within 3-5 years. While Q4 2025 saw revenue growth and the balance sheet is strong, the Q1 2026 guidance projects a significant decline in revenue and a shift to a net loss. Critically, new prescriptions for its core product, NERLYNX, are declining. The primary growth catalyst (Alisertib data) mentioned in previous analyses is entirely absent from current market intelligence, leaving no clear path for exponential growth. With no identified competitive advantages, external catalysts, or strong insider/institutional conviction, and a contracting core business, the company lacks a compelling narrative for substantial future upside. The strong balance sheet offers some stability but does not offset the fundamental growth challenges.